Genentech
1 DNA Way South, San Francisco, CA 94080
www.gene.com

About Genentech
Founded more than 40 years ago as the first biotechnology company, Genentech is dedicated to the rigorous pursuit of science and the development and delivery of life-changing medicines for people facing serious diseases. Headquartered in South San Francisco, California and a proud member of the Roche Group, our community is united by a common purpose and sense of urgency to transform the future of healthcare. Learn more at gene.com.

Representatives
David Jacobs, Respiratory Therapeutic Area Managers
717-802-5253
djacobs@gene.com

Kelli Smith, Respiratory Therapeutic Area Manager
609-389-3469
smithk62@gene.com

Chris Lehan, Respiratory Therapeutic Area Manager
240-418-5452
lehanc@gene.com
​
Bob Shontz, Respiratory Therapeutic Area Manager
412-719-0545
rshontz@gene.com

Resources
IDENTIFYING APPROPRIATE PATIENTS FOR SELF-INJECTION
Allergic Asthma CVA
Representatives will be available to meet with attendees at the following times:
Friday, June 25
7:30 a.m. - 7:50 a.m.
10:15 a.m. - 10:45 a.m.
Saturday, June 26
7:30 a.m. - 7:50 a.m.
9:30 a.m. - 10:00 a.m.
11:45 a.m. - 12:15 p.m.
XOLAIR
https://www.gene.com/download/pdf/xolair_prescribing.pdf
XOLAIR® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat: 
  • moderate to severe persistent asthma in people 6 years of age and older whose asthma symptoms are not well controlled with asthma medicines called inhaled corticosteroids. A skin or blood test is performed to see if you have allergies to year-round allergens. It is not known if XOLAIR is safe and effective in people with asthma under 6 years of age.
  • nasal polyps in people 18 years of age and older when medicines to treat nasal polyps called nasal corticosteroids have not worked well enough. It is not known if XOLAIR is safe and effective in people with nasal polyps under 18 years of age.
  • chronic idiopathic urticaria (CIU, chronic hives without a known cause) in people 12 years of age and older who continue to have hives that are not controlled with H1 antihistamine treatment. It is not known if XOLAIR is safe and effective in people with CIU under 12 years of age.
XOLAIR is not used to treat other allergic conditions, other forms of hives, or sudden breathing problems.
Resources
Nasal Polyps At-Approval Brochure
​XOLAIR CIU CVA